Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
about
Statistical methods used to test for agreement of medical instruments measuring continuous variables in method comparison studies: a systematic reviewParenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study.Variability between laboratories performing coagulation tests with identical platforms: a nationwide evaluation studyEstablishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.Therapeutic monitoring of unfractionated heparin - trials and tribulations.A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.The PiCT(®) test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study.Controversies in heparin monitoring.Protocolled Redefinition of the Therapeutic Range for Unfractionated Heparin: Lost in Translation?Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.
P2860
Q28729200-58CAE031-6014-423A-B6E2-615DB9C9F3DAQ33399576-B1FFDB85-C6AB-4574-B3AE-D8EE5B07B4EDQ35154142-0094C434-74C5-468E-8038-948DA46A43C6Q35525678-46AD2475-B202-437F-BFAD-B2E59FB969A1Q36689644-44EB441E-2765-4D0A-B952-5D21A01B58CCQ37318663-E0153A95-D4DD-4AC1-AA5D-10B99109E135Q37867278-AE0092DD-DB8F-4652-84C9-3BD1F366C74CQ38005321-C8BDCF91-7CE3-4D29-9B01-54CD4466046DQ38669011-31030932-E98C-42BD-9E98-5F1A218DF577Q39471291-5F5A5714-E36C-4BA3-A8E2-4016DD1E5596Q44315763-0C44BF6C-0AEB-4253-A706-0D81E4D67D1FQ45857879-1E876DCB-EA5D-4CCF-A55E-3525D0616C62Q46318417-DA8C2167-DDC4-4A47-B96B-0D630F9903A5Q48738998-E0101154-5520-460E-967E-639F8516B3F5Q50047585-B96D3A40-1913-4C89-9C0E-A08378D54F9C
P2860
Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Interlaboratory agreement in t ...... d partial thromboplastin time.
@en
Interlaboratory agreement in t ...... d partial thromboplastin time.
@nl
type
label
Interlaboratory agreement in t ...... d partial thromboplastin time.
@en
Interlaboratory agreement in t ...... d partial thromboplastin time.
@nl
prefLabel
Interlaboratory agreement in t ...... d partial thromboplastin time.
@en
Interlaboratory agreement in t ...... d partial thromboplastin time.
@nl
P2093
P1476
Interlaboratory agreement in t ...... ed partial thromboplastin time
@en
P2093
B A Konkle
B Ptashkin
E S Pollak
H C Whinna
P356
10.1111/J.1538-7836.2008.03224.X
P577
2008-11-11T00:00:00Z